RESUMEN
There has been considerable research in recent years on dietary factors and/or nutritional elements that might impact melanoma risk. A wide variety of dietary compounds have been studied, but only a selected group will be discussed in this review. Many have promising in vitro evidence supporting their potential, and some have been associated with decreased melanoma risk in epidemiologic studies; however, data from randomized controlled trials in humans are lacking. Future studies may be able to clarify the potential role of dietary components in melanoma risk reduction.
Asunto(s)
Dieta , Melanoma , Humanos , Melanoma/etiología , Melanoma/prevención & controlRESUMEN
Concern over the corporatization of medicine has existed since the late 1800s and continues to grow today in the face of large-scale mergers, vertical integration of health care services, and private equity (PE) investment in dermatology practices. Although academic departments have traditionally been viewed as exempt from Corporate Practice of Medicine (CPOM) laws, they face the same health care landscape and cultural pressures as private and PE-backed practices, as well as some unique financial challenges. To adapt to these difficult realities, academic dermatology has embraced new models of care, some of which mirror the controversial strategies used by PE-backed practices to maximize profit. We explore the corporatization of academic dermatology and its manifestations in changing practice patterns, patient care, education, and research.
Asunto(s)
Dermatología/economía , Práctica Privada/economía , Corporaciones Profesionales/economía , Atención a la Salud/economía , Humanos , Atención al Paciente/economía , Pautas de la Práctica en Medicina/economía , Corporaciones Profesionales/legislación & jurisprudenciaAsunto(s)
Anticuerpos Monoclonales Humanizados/administración & dosificación , Eccema Dishidrótico/tratamiento farmacológico , Dermatosis del Pie/tratamiento farmacológico , Dermatosis de la Mano/tratamiento farmacológico , Adulto , Anciano , Anticuerpos Monoclonales Humanizados/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del TratamientoAsunto(s)
Dermatología/educación , Internado y Residencia/estadística & datos numéricos , Acoso Sexual/estadística & datos numéricos , Adulto , Dermatología/estadística & datos numéricos , Femenino , Humanos , Masculino , Minorías Sexuales y de Género/estadística & datos numéricos , Encuestas y Cuestionarios/estadística & datos numéricos , Estados Unidos , Adulto JovenAsunto(s)
Materiales Biocompatibles , Dermatología/instrumentación , Prioridad del Paciente/estadística & datos numéricos , Suturas/ética , Vegetarianos/estadística & datos numéricos , Adolescente , Adulto , Anciano , Animales , Dermatología/ética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Encuestas y Cuestionarios/estadística & datos numéricos , Vegetarianos/psicología , Adulto JovenRESUMEN
Dermatomyositis (DM) is an idiopathic inflammatory myopathy that is clinically heterogeneous and that can be difficult to diagnose. Cutaneous manifestations sometimes vary and may or may not parallel myositis and systemic involvement in time course or severity. Recent developments in our understanding of myositis-specific antibodies have the potential to change the diagnostic landscape of DM for dermatologists. Although phenotypic overlap exists, anti-Mi2, -MDA5, -NXP2, -TIF1, and -SAE antibodies may be correlated with distinct DM subtypes in terms of cutaneous manifestations, systemic involvement, and malignancy risk. This review highlights new findings on the DM-specific myositis-specific antibodies and their clinical associations in both adults and children.
Asunto(s)
Autoanticuerpos/inmunología , Autoantígenos/inmunología , Dermatomiositis/inmunología , Enfermedades Pulmonares Intersticiales/inmunología , Neoplasias/inmunología , Adulto , Autoantígenos/genética , Biopsia , Niño , Dermatomiositis/complicaciones , Dermatomiositis/epidemiología , Dermatomiositis/genética , Humanos , Enfermedades Pulmonares Intersticiales/genética , Músculo Esquelético/inmunología , Músculo Esquelético/patología , Neoplasias/genética , Factores de Riesgo , Piel/inmunología , Piel/patologíaRESUMEN
The second article in this continuing medical education series reviews the initial evaluation of patients with suspected dermatomyositis (DM), the relevant work-up for malignancy and interstitial lung disease once a diagnosis of DM is made, and treatment recommendations for patients with DM based on disease severity, the presence of systemic symptoms, and myositis-specific antibody (MSA) profiles. This review emphasizes the emerging role of MSAs in the diagnosis of DM and highlights how MSAs can be used to guide the appropriate work-up for malignancy and interstitial lung disease. The treatment approach proposed by this continuing medical education series discusses both established and novel therapies for DM and highlights the importance of considering lesion type, degree of muscle involvement, presence of systemic symptoms, presence of MSAs, and patient age when determining the best treatment approach for a patient with DM.
Asunto(s)
Autoanticuerpos/aislamiento & purificación , Dermatomiositis/diagnóstico , Inmunoterapia/métodos , Enfermedades Pulmonares Intersticiales/prevención & control , Neoplasias/prevención & control , Adulto , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Autoantígenos/inmunología , Biopsia , Niño , Dermatomiositis/complicaciones , Dermatomiositis/inmunología , Dermatomiositis/terapia , Humanos , Inmunoterapia/tendencias , Enfermedades Pulmonares Intersticiales/inmunología , Músculo Esquelético/inmunología , Músculo Esquelético/patología , Neoplasias/inmunología , Factores de Riesgo , Índice de Severidad de la Enfermedad , Piel/inmunología , Piel/patologíaAsunto(s)
Anticuerpos Monoclonales Humanizados/efectos adversos , Fármacos Dermatológicos/efectos adversos , Eritema/inducido químicamente , Exantema/inducido químicamente , Dermatosis Facial/inducido químicamente , Adolescente , Adulto , Anciano , Dermatitis Atópica/tratamiento farmacológico , Erupciones por Medicamentos/etiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto JovenRESUMEN
Gender bias and gender-based discrimination and harassment are known to affect women across all fields of medicine. Despite acknowledgement of a persistent "gender gap" in dermatology, there has been little formal research to date exploring how gender bias may be impacting the careers of women in the field. In this commentary, we discuss the results of an anonymous, online survey that assessed perceived effects of gender bias and sexual harassment on professional development among women dermatologists. The large majority of respondents reported experiencing significant gender-based obstacles to career advancement in either their current or past practice settings. Lack of equal professional support between men and women and discrimination based on parental status were commonly noted themes. A majority of respondents also reported having experienced some form of sexual harassment in the workplace. These trends, while not unique to the field of dermatology, are unacceptable and need to be confronted and rectified. Promoting gender equity in dermatology is important for clinicians, patients, and the future of dermatology.
RESUMEN
There are multiple, genetically distinct pathways that give rise to melanoma. Melanomas on sun-damaged skin (MSDS), including lentigo maligna and desmoplastic melanoma, have distinct genetic profiles and are uniquely linked to chronic ultraviolet exposure. In this article, we discuss the etiologies of lentigo maligna and desmoplastic melanoma, emerging diagnostic adjuncts that might be helpful for accurately identifying these lesions, and the clinical relevance of their frequent co-occurrence. We present unique and overlapping features of these entities and discuss challenges in MSDS management, including margin assessment, excision, and the potential role of nonsurgical therapy. Last, we address the role of immunotherapy in invasive disease. Understanding MSDS as distinct from melanoma arising on intermittently sun-exposed or sun-protected skin will ultimately help optimize patient outcomes.